CenTrial Logo

Improving Treatment for Bipolar Depression


Clinical trial investigates the effectiveness of antidepressant maintenance treatment for bipolar depression

Bipolar I depression is a mental health condition that affects a person's mood, causing extreme shifts between periods of intense sadness (depression) and unusually high energy levels (mania). People with bipolar depression often need medication to manage their symptoms and maintain stability.

Antidepressants are used to treat acute depression in patients with bipolar I disorder, but their effect as maintenance treatment after the remission of depression has not been well studied.

A clinical trial investigated the effectiveness of using antidepressant medication as a maintenance treatment after the remission of bipolar I depression. 

Clinical Trial

The trial aimed to discover if long-term antidepressant therapy after the remission of bipolar depression could help in preventing further depression episodes and their associated complications. 

177 participants were recruited who had remission of bipolar I depression. 90 patients were assigned to continue treatment with the prescribed antidepressant for 52 weeks (52-week group) and 87 were assigned to switch to placebo at 8 weeks (8-week group).
The researchers tracked these participants over an extended period to observe the effects of prolonged antidepressant use.

The primary outcome was any mood episode, as defined by scores on scales measuring symptoms of hypomania or mania, depression, suicidality, and mood-episode severity; additional treatment or hospitalization for mood symptoms; or attempted or completed suicide. Key secondary outcomes included the time to an episode of mania or hypomania or depression.

Key Findings

The clinical trial revealed important insights into the duration of antidepressant maintenance for bipolar I depression. The researchers found that continuing to take antidepressants beyond the usual 8-week period did not lead to better outcomes for participants. At 52 weeks, 28 of the patients in the 52-week group (31%) and 40 in the 8-week group (46%) had a primary-outcome event. This difference between the two groups was not statistically significant.

Why It Matters

The findings of this study have significant implications for individuals living with bipolar I depression and their healthcare providers. By determining the optimal duration of adjunctive antidepressant use, doctors can now tailor their treatment plans to provide the best care possible. This research helps strike a balance between the benefits of antidepressant medication and the potential risks associated with prolonged use.


The clinical trial shed light on the duration of antidepressant maintenance in the treatment of bipolar I depression. The research highlights that in patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as compared with treatment for 8 weeks in preventing relapse of any mood episode. These findings offer valuable guidance to healthcare professionals when designing personalized treatment plans for individuals with bipolar I depression.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

20,000 clinical trials are seeking participants.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.